Product Description
PRAME TCR/IL-15 NK (SY-307) is being developed by Syena, an oncology-focused product company launched by Replay and MD Anderson based on the scientific discoveries of Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson. Syena has an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) T cell receptor (TCR). The engineered PRAME-targeted TCR NK cell therapy is developed from cord blood-derived NK cells that express a high affinity TCR targeting the PRAME tumor-associated neoantigen. (Sourced from: https://www.mdanderson.org/newsroom/novel-PRAME-targeted-TCR-NK-cell-therapy-receives-FDA-IND-clearance-hematologic-cancers.h00-159696756.html#:~:text=The%20University%20of%20Texas%20MD,NK)%20cell%20therapy%20for%20relapsed%2F)
Mechanisms of Action: Cell Therapy,NK,PRAME,IL15
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Syena
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia|Myelodysplastic Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|